Bristol-Myers (NYSE:BMY) Rating Reaffirmed
In a recent research report announced this morning, Barclays kept steady their “Equal Weight” rating on Bristol-Myers (NYSE:BMY) shares. The PT would indicate a possible upside of 2.99% from company’s stock price.
From a total of 18 analysts covering Bristol-Myers Squibb Company (NYSE:BMY) stock, 12 rate it a ”Buy”, 0 a “Sell”, and 9 a ”Hold”. This means that 57% of the ratings are positive. The highest target price is $80 while the lowest target price is $61. The mean of all analyst targets is $72.44 with a 5.19% above today’s ($67.97) stock price. Bristol-Myers Squibb Company was the topic of 10 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. UBS upgraded shares on September 29 to “Buy” rating.
Approximately 2.32 million shares of stock traded hands. Bristol-Myers Squibb Co (NYSE:BMY) has risen 3.83% since April 28, 2015 and is uptrending. It has outperformed by 5.45% the S&P500.
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The company has a market cap of $114.78 billion. The Company’s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It has 64.23 P/E ratio. The Firm makes its products in the United States, Puerto Rico and in six foreign countries.
According to Zacks Investment Research, “Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.” Get a free copy of the Zacks research report on Bristol-Myers Squibb Co (BMY)